Today at the blog some of us have been dealing with the issue of Covid being a pandemic of the vaccinated. So, why is this? One hypothesis has been offered by Dr. Harvey Risch, an epidemiology professor at the Yale School of Public Health. The spike proteins in the Pfizer and Moderna vaxxes are based upon the original SARS-CoV-2, but things have moved on in the viral world, with BA.4 and BA. 5 now dominating. And, here is the problem: “The problem with that is, of course, that when the spike protein changes because of new strains of the virus, that the ability of the immune system to make antibodies that correlate to the new strains becomes reduced to the point where it may be almost ineffective over longer periods of time. “What that means is they become interfering antibodies, instead of neutralizing antibodies,” Risch said. “And that’s the reason I believe that we’ve seen what’s called negative benefit—negative vaccine efficacy over longer time—over four to six to eight months after the last vaccine dose, that one sees the benefit of the vaccines turn negative.”
What this implies, I believe, is that the vaxxes therefore necessarily will do more harm than good, contrary to the mainstream Big Pharma narrative.
“The antibodies triggered by COVID-19 vaccines are interfering with people’s immune systems as newer virus variants emerge, Dr. Harvey Risch said.
The two most widely-used vaccines in the United States, produced by Pfizer and Moderna, both work by sending messenger RNA into muscle cells, where they produce a piece of the spike protein from the virus that causes COVID-19. The spike protein triggers the production of antibodies, which are believed to help prevent infection by SARS-CoV-2, which causes COVID-19, and fight illness if one still gets infected.
But the vaccines are based on the spike protein from the original virus variant, which was displaced early in the pandemic. Since then, a series of newer strains have become dominant around the world, with the latest being BA.5.
“The vaccines only make a very narrow range of antibodies to the spike protein,” compared to the broader exposure experienced when one gets infected, Risch, an epidemiology professor at the Yale School of Public Health, told EpochTV’s “American Thought Leaders.”
“The problem with that is, of course, that when the spike protein changes because of new strains of the virus, that the ability of the immune system to make antibodies that correlate to the new strains becomes reduced to the point where it may be almost ineffective over longer periods of time,” he added.
That leads to the antibodies being triggered by the vaccines not binding strongly enough to neutralize.
“What that means is they become interfering antibodies, instead of neutralizing antibodies,” Risch said. “And that’s the reason I believe that we’ve seen what’s called negative benefit—negative vaccine efficacy over longer time—over four to six to eight months after the last vaccine dose, that one sees the benefit of the vaccines turn negative.”
Worse Effectiveness Amid Spike Protein Changes
A number of recent studies have indicated that people who were vaccinated are more likely to get infected with COVID-19 after a period of time, including Pfizer’s clinical trial in young children (pdf). Some real-world data also show higher rates of infection among the vaccinated. Other research indicates vaccines still provide some protection as time wears on after getting a shot, but the protection does wane considerably. The research all deals with the Omicron variant, which became dominant in late 2021, and its subvariants.
There were relatively few changes to the spike protein as the initial variants emerged, which meant that vaccines still provided a fairly good benefit, Risch said. But Omicron started off with more than 50 changes to the spike protein, and subvariants of Omicron such as BA.5 have added more.
He pointed to data reported by United Kingdom health authorities in March (pdf)—the officials stopped reporting the data after that—pegging people who had received both a primary vaccination series and a booster as having three times the rate of symptomatic infection as unvaccinated people.
“After the second dose of the mRNA vaccines, it looks like they provide a benefit against symptomatic infection for … most people for maybe 10 to 12 weeks,” Risch said.
“After the first booster, the third dose, that drops to six to eight weeks. After the fourth booster, it may be as short as four weeks before the efficacy wears off and begins to turn negative.”